Brand Intelligence Graph
Company Overview
About Alto Neuroscience
Alto Neuroscience is a publicly-listed (Nasdaq: ANRO) clinical-stage biotech applying biomarker-stratified patient selection to psychiatry — matching patients to drugs based on brain biology rather than symptom checklists that have historically produced inconsistent treatment outcomes. The company raised a $120 million PIPE in 2026 to fund Phase 2b development of ALTO-207, a fixed-dose combination of pramipexole and ondansetron for treatment-resistant depression (TRD). The FDA has granted Fast Track designation for ALTO-101, and Alto has four clinical data readouts expected through 2027.
Business Model & Competitive Advantage
Treatment-resistant depression affects approximately 3 million Americans who fail two or more adequate antidepressant trials. Existing treatments for TRD (ketamine/esketamine, ECT, TMS) are effective but require clinic visits and carry significant side effect profiles. Alto's oral fixed-dose combination targeting TRD represents a potentially more accessible outpatient treatment option.
Competitive Landscape 2025–2026
The biomarker stratification approach is Alto's scientific differentiator: conventional antidepressant trials enroll unselected patients and achieve 30-40% response rates. Alto's platform uses neuroimaging, EEG, and genetic biomarkers to identify the 30-40% of patients most likely to respond to each specific drug mechanism — enabling clinical trials with higher response rates in the selected subpopulation and regulatory filings for a defined biomarker-positive indication.
Key Differentiators
Emerging Innovator
Alto Neuroscience is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Schrödinger
Schrödinger was founded in 1990 by Richard Friesner and David Pearlman in New York City, building physics-based computational methods for molecular simulation. For over 30 years the company has develo
Compare Alto Neuroscience with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Alto Neuroscience? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Alto Neuroscience Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Alto Neuroscience vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →